TAB2

Across TCGA pan-cancer cohorts, TAB2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TAB2 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher TAB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, UCEC, and STAD are the cancer types where TAB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.068	0.830	<.001	36	view →
UCEC	DFS	Median	II,III,IV	1.000	0.434	.007	36	view →
STAD	OS	Median	All	0.184	0.730	.001	18	view →
LIHC	OS	Median	All	0.198	0.777	.006	18	view →
READ	DFS	Median	All	0.111	0.799	.001	12	view →
BLCA	OS	Median	IV	0.057	0.600	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TAB2–CESC (OS)

Open the CESC breakdown →